Table 1.

Characteristics of studies included in the meta-analysis

Author Year	Country	Mucosal protective agents	Patients number	Intervention	Duration (days)
Kato 2010	Japan	Rebamipide	31	RPZ 10 mg/day	28
			31	RPZ + rebamipide 300 mg/day
Fujiwara 2011	Japan	Rebamipide	31	OPZ 20 mg/day	56
			30	OPZ + rebamipide 300 mg/day
Araki 2012	Japan	Rebamipide	42	OPZ 20 mg/day, LPZ 30 mg/day or RPZ 10 mg/day	28
			45	PPI + rebamipide 300 mg/day
Kobayashi 2012	Japan	Rebamipide	85	OPZ 20 mg/day or LPZ 30 mg/day	28–42
			85	PPI + rebamipide 300 mg/day
Shin 2012	Korea	Rebamipide	129	Pantprazole 40 mg/day	28
			126	Pantprazole + rebamipide 300 mg/day
Takayama 2013	Japan	Rebamipide	44	LPZ 30 mg/day	28/56
			45	LPZ 30 mg/day, 5 days; then rebamipide 300 mg/day
Asakuma 2009	Japan	Ecabet	27	RPZ 20 mg/day	28/56
			28	RPZ + ecabet 3 g/day
Hyun 2010	Korea	Ecabet	38	LPZ 30 mg/day	28
			38	LPZ 30 mg/day, 7 days; then ecabet 3 g/day
Inaba 2010	Japan	Polaprezinc	80	LPZ 30 mg/day	56
			79	LPZ + polaprezinc 150 mg/day
Yoshida 2013	Japan	Polaprezinc	27	OPZ 20 mg/day	56
			23	OPZ + polaprezinc 150 mg/day
Miyahara 2013	Japan	Irsogladine	45	PPI	28
			51	PPI + irsogladine

RPZ: rabeprazole, OPZ: omeprazole, LPZ: lansoprazole.